Final-Day Subscription and the Grey Market Signal

The initial public offering of Manipal Health Enterprises, one of India’s largest hospital chains, remained below full subscription with just hours left on the final bidding day. By 11:07 a.m. on July 31, the Rs 9,275-crore issue had gathered bids for only 50% of the shares on offer, according to NSE data. Qualified institutional buyers, whose quota is typically key to an IPO’s success, led with 62% subscription, while retail participation stood at 54% and the non-institutional portion languished at 18%.

The market’s muted enthusiasm was mirrored in the grey market, where the unlisted shares of the company were trading with a marginal premium of Rs 5 over the upper price band of Rs 590. That points to a listing price of roughly Rs 595 and a nominal gain of around 1%, according to platforms like Investorgain and IPO Watch—well below the double-digit premiums seen in recent healthcare listings.

The IPO consists of a fresh issue of Rs 8,000 crore and an offer for sale by existing shareholders, including promoter group entities, TPG and Novo Holdings. The OFS size was pruned from 4.32 crore shares to 2.16 crore shares since the draft prospectus was filed in March 2026, a move that may have partially allayed concerns about early investor exits. Retail applicants can bid for a minimum lot of 25 shares, translating to an investment of Rs 14,750 at the top end. Allotment is expected on August 3, with listing on BSE and NSE slated for August 5.

What the Pricing and Proposals Reveal About Manipal Health’s Outlook

A Fully Priced Offer and the 85.4x P/E Question

At the upper price band, Manipal Health is seeking a post-issue market capitalisation of Rs 77,605.6 crore and a price-to-earnings multiple of 85.4 times its FY26 net profit of Rs 892.32 crore. Brokerage Anand Rathi called the pricing “fully priced,” a label that can deter short-term speculators. Still, the firm assigned a ‘Subscribe-Long Term’ rating, arguing the company’s expansion trajectory and leadership in tertiary care can justify the premium over time. This tension between high entry valuation and long-term growth potential largely explains the tepid demand from non-institutional investors who often chase listing pops.

Advertisement

Where the Proceeds Will Go

The fresh capital is earmarked primarily to repay borrowings of subsidiary Manipal Hospitals Private Ltd., acquire a minority stake in Sahyadri Hospitals Private, and for general corporate purposes. Debt repayment could improve balance-sheet strength and free up cash for further bed additions. The proposed acquisition of a stake in Sahyadri Hospitals hints at an inorganic push in the western Indian market, complementing the chain’s existing 49 hospitals and 13,037 licensed beds across 14 states. If executed well, the move could strengthen regional presence without the lead time of greenfield projects.

How Brokerages Are Reading the Script

Master Capital Services struck a favorable tone, arguing the company is well positioned to capture rising healthcare demand through its pan-India network and advanced clinical capabilities. Anand Rathi’s more cautious endorsement noted that the full pricing means near-term trading gains are unlikely, but the long-term story holds. Both views align with the grey market’s own verdict: the IPO is being treated as a holding play rather than a quick flip.

Key Points for Investors Ahead of Listing

  • Scrutinise the P/E in context. At 85.4x, the valuation is steep. Compare with listed peers such as Apollo Hospitals and Max Healthcare to assess whether the growth trajectory warrants the premium.
  • Watch the allotment and listing timeline. Basis of allotment is August 3 and listing is August 5. A low grey market premium suggests the listing may open near the issue price, offering little immediate profit for short-term traders but a potential entry point for long-term investors.
  • Evaluate the use-of-proceeds strategy. Debt repayment at the subsidiary level and the Sahyadri Hospitals stake purchase signal both financial consolidation and targeted expansion. Investors should weigh the pace at which these moves can lift earnings.
  • Factor in the OFS reduction. The scaling back of the offer for sale indicates that existing shareholders are offloading fewer shares than originally planned, which reduces immediate selling pressure but also reflects a conscious decision to retain stake.

Risk & Opportunity Assessment

Commercial RiskMediumThe IPO is fully priced at a high PE multiple, and subdued subscription suggests lukewarm investor appetite. Flattish grey market premiums underscore limited listing gains, though robust FY26 revenue of Rs 10,335 crore provides a solid base.
Competitive RiskMediumThe pan-India hospital sector is intensely competitive, with players like Apollo and Max Healthcare holding significant mindshare. Manipal’s regional network and bed expansion are positive, but market share gains are gradual.
Regulatory RiskLowNo specific regulatory hurdles or policy changes affecting hospital chains have been flagged in the IPO documents, and healthcare in India remains a priority sector.
Reputation RiskLowManipal Health is an established brand with over 49 hospitals. No adverse clinical or governance events are cited that could immediately dent its reputation.
Technology DisruptionLowHealthcare delivery, especially in tertiary care, is less prone to rapid technology-led disruption than, for example, primary diagnostics. The company’s heavy asset base insulates it from sudden obsolescence.
Commercial OpportunityHighRising healthcare demand, under-penetration of organised hospital care, and planned capacity expansion (including the Sahyadri stake) position the chain to capture a larger share of the growing market, as noted by brokerages.